Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Sanofi
  6. News
  7. Summary
    SAN   FR0000120578

SANOFI

(SAN)
  Report
Real-time Euronext Paris  -  11:37 2022-09-23 am EDT
78.81 EUR   -0.05%
09/21SANOFI : Deutsche Bank sticks Neutral
MD
09/20Haleon rejects Zantac indemnification requests from GSK, Pfizer
RE
09/19France's Biocorp Gets CE Marking for Accessory Medical Device for Sanofi's Insulin Injection Pens
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sector Update: Health Care

08/17/2022 | 03:38pm EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
NASDAQ COMPOSITE -1.80% 10867.93 Real-time Quote.-30.53%
SANOFI -0.05% 78.81 Real-time Quote.-11.03%
All news about SANOFI
09/21SANOFI : Deutsche Bank sticks Neutral
MD
09/20Haleon rejects Zantac indemnification requests from GSK, Pfizer
RE
09/19France's Biocorp Gets CE Marking for Accessory Medical Device for Sanofi's Insulin Inje..
MT
09/18Sanofi Wins European Medicines Agency's Positive Opinion For Rare Blood Disorder Drug
MT
09/16European ADRs Move Lower in Friday Trading
MT
09/16Regeneron pharmaceuticals, inc. - positive dupixent phase 3 data in children aged 6 mon..
AQ
09/16SECTOR UPDATE : Health Care Stocks Mixed Premarket Friday
MT
09/16AstraZeneca, Sanofi's Respiratory Tract Disease Drug Recommended for Approval in Europe..
MT
09/16Regeneron Pharmaceuticals, Sanofi Say Atopic Dermatitis Drug Improved Skin Clearance in..
MT
09/16British Pharma Giant AstraZeneca Scores Positive Recommendations for Two Respiratory Dr..
MT
More news
Analyst Recommendations on SANOFI
More recommendations
Financials
Sales 2022 42 332 M 41 159 M 41 159 M
Net income 2022 8 285 M 8 055 M 8 055 M
Net Debt 2022 7 796 M 7 580 M 7 580 M
P/E ratio 2022 12,0x
Yield 2022 4,53%
Capitalization 98 832 M 96 093 M 96 093 M
EV / Sales 2022 2,52x
EV / Sales 2023 2,31x
Nbr of Employees 95 442
Free-Float 87,9%
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 78,81 €
Average target price 110,53 €
Spread / Average Target 40,3%
EPS Revisions
Managers and Directors
Paul Hudson Chief Executive Officer & Director
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Serge Weinberg Director
John C. Reed EVP & Global Head-Research & Development
Nestle Frank Global Head-Immunology Therapeutic Research Area
Sector and Competitors
1st jan.Capi. (M$)
SANOFI-11.03%96 093
JOHNSON & JOHNSON-2.54%438 337
ELI LILLY AND COMPANY12.54%295 941
ROCHE HOLDING AG-18.41%259 291
ABBVIE INC.5.66%252 944
PFIZER, INC.-25.35%247 392